The Lancet published CanSino Biologics Inc.’s Phase III clinical trial results on the safety and efficacy of the company’s recombinant novel coronavirus vaccine, Convidecia.

CanSino Biologics Inc.’s single-dose Covid-19 vaccine – given at a lower dosage than that for adults – is safe and triggers an immune response in children aged 6-17, results from a small trial showed.

Antibody levels in people inoculated with CanSino Biologics’ (CanSinoBIO) single-dose Covid-19 vaccine fell by some 30 percent after six months, however a booster shot could offer a significant lift, a senior executive said on Aug. 5.

An inhalation version of CanSino Biologics’ Covid-19 vaccine is being tested in a Phase II clinical trial, Chief Executive Yu Xuefeng said on June 2.

China’s CanSino Biologics will initiate clinical trials of an experimental Covid-19 vaccine that is inhaled, instead of injected.

China’s CanSino Biologics Inc. said the efficacy rate for the company’s single-dose Covid-19 vaccine may fall over time although it should still have a rate of 50 percent or more five to six months after inoculation.

As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.